NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

OPTIMISE-CKD Study_current Clinical Landscape in Spain

CompletedN/A

Sponsor: AstraZeneca

Conditions: Renal Disease

Interventions: Pre-pricing & reimbursement, incident renal disease cohort (study observation period 2020- 2024), Post-pricing & reimbursement, incident renal disease cohort (study observation period 2023-2024)

Countries: Spain

OPTIMISE-CKD is a retrospective, observational study, using secondary data. The incidence of renal disease, including CKD, using eGFR or UACR laboratory measurements and diagnostic codes will be assessed in the study population. The study will also assess the incidence of selected cardiovascular and renal events and the current use of kidney-protective treatments

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

Age ≥18 years as of study index date

* With renal function measured as either of the following:

  * At least 1 UACR measure of ≥30 mg/g; OR
  * At least 2 eGFR measures taken ≥90 days apart, of which both eGFR is ≤75 ml/min/1.73m2 ; OR
* registered with Chronic Kidney Disease (CKD) diagnosis in the medical history (without biochemical confirmation)

Exclusion Criteria:

* History of stage 5 CKD, dialysis, organ transplant, type 1 diabetes, or gestational diabetes on or before the start date of the observation period

Locations (1)

Seville, Spain